“The endocannabinoid system (ECS) regulates functions throughout human physiology, including neuropsychiatric, cardiovascular, autonomic, metabolic, and inflammatory states”, begins the study’s abstract, which was published in-print by the journal Cannabis and Cannabinoid Research. “The complex cellular interactions regulated by the ECS suggest a potential for vascular disease and stroke prevention by augmenting central nervous and immune cell endocannabinoid signaling.”
Cannabidiol (CBD), a nonpsychoactive constituent of Cannabis, “is an immediate therapeutic candidate both for potentiating endocannabinoid signaling and for acting at multiple pharmacological targets.” According to researchers at Mayo Clinic’s Department of Neurology, this “speculative synthesis explores the current state of knowledge of the ECS and suggests CBD as a therapeutic candidate for stroke prevention by exerting favorable augmentation of the homeostatic effects of the ECS and, in turn, improving the metabolic syndrome, while simultaneously stalling the development of atherosclerosis.”
Read the abstract of the study at: https://www.ncbi.nlm.nih.gov/pubmed/29098188